A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

The body absorbs the carbon in a way that “may support weight loss,” according to a new study, but carbonated drinks are not a “standalone solution”

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That changed after a special on weight loss with experts and clinicians that she taped in July 2023. The panel discussion left her with her “biggest aha moment” about the medication.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,

Obesity expert Dr. Naomi Parrella of Rush University joins Marie Saavedra to talk about the new study and the impact for patients.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,